Simcere and Stanford partner to develop IPF therapies

Simcere Pharmaceutical has entered a research collaboration agreement with Stanford Medicine to develop new therapies for IPF. If the research is successful, Simcere may in-license the molecule and obtain all global rights to the product. IPF is a chronic, progressive lung disease with no known cause, marked by the development of fibrosis in the lung interstitium. Credit: SkazovD / Shutterstock.com. Simcere Pharmaceutical Group has entered a research collaboration agreement with Stanford Medicine to develop new therapies for idiopathic pulmonary fibrosis (IPF). Under the deal, Simcere will provide funding for exploratory research on a first-in-class novel molecule in the respiratory field.…

Source: Pharmaceutical Technology